Table 1 |
|||
|
Immunohistochemistry |
|||
|
Antibody |
Expression in SPC |
Expression in IMT |
Source/Dilution |
|
|
|||
|
First stainings |
|||
|
|
|||
|
Vimentin * |
++ |
++ |
DAKO, mouse, 1:800 |
|
PanCytokeratin AE1/3 * |
+ |
NR |
DAKO, mouse, 1:100 |
|
EMA |
+ |
+ (weak only) |
LOXO, mouse, 1:20 |
|
ALK-1 * |
NR |
+ |
DAKO, mouse, 1:20 |
|
smooth muscle Actin |
++ |
NR |
Beckman Coulter, mouse, 1:20 |
|
Desmin |
NR |
NR |
DAKO, mouse, 1:400 |
|
S100 |
NR |
NR |
DAKO, rabbit, 1:2000 |
|
CD34 |
NR |
NR |
DAKO, mouse, 1:100 |
|
CD117 |
NR |
NR |
DAKO, mouse, 1:100 |
|
Ki67 * |
++ 60–80% |
+ 5–10% |
DAKO, mouse, 1:200 |
|
|
|||
|
Additional stainings |
|||
|
|
|||
|
PanCytokeratin KL1 * |
+ |
NR |
Beckman Coulter, mouse, 1:40 |
|
PanCytokeratin MNF116 |
NR (but epithelium +) |
NR |
DAKO, mouse, 1:50 |
|
Cytokeratin 5/6 |
+ (weak only) |
NR |
DAKO, mouse, 1:50 |
|
Cytokeratin 7 |
NR |
NR |
DAKO, mouse, 1:20 |
|
CD68 |
NR |
NR |
Kiel, ascites, 1:20000 |
|
CD30 |
NR |
NR |
DAKO, mouse, 1:5 |
|
CD56 |
NR |
NR |
DAKO, mouse, 1:10 |
|
Her2Neu |
NR |
NR |
DAKO, rabbit, 1:100 |
|
Estrogen receptor |
NR |
NR |
DAKO, mouse, 1:10 |
|
Progesteron receptor |
NR |
NR |
DAKO, mouse, 1:10 |
|
p53 |
+ |
+ |
DAKO, mouse, 1:20 |
|
p63 * |
++ |
NR |
Neomarkers, mouse, 1:200 |
|
p21 |
++ |
++ |
Dianova, rat, 1:20 |
|
Cyclin D1 |
+ |
+ |
LOXO, mouse, 1:20 |
|
Bcl-2 |
+ (weak cytoplasmatic) |
++ |
DAKO, mouse, 1:400 |
|
Rb |
+ |
++ |
Neomarkers, mouse 1:50 |
|
HHV 8 |
NR |
NR |
Tebu, rat, 1:200 |
|
HPV |
NR |
NR |
Virofem, mouse conc. |
|
|
|||
|
Used antibodies with expression pattern in spindle cell carcinoma (SPC) and inflammatory myofibroblastic tumor (IMT) as well as source and dilution. Staining started with antibodies in the upper part, followed by additional stainings, listed below. strong positive reaction (++), positive reaction (+), no reaction (NR), recommended for differential diagnosis (*). |
|||
|
Völker et al. Diagnostic Pathology 2007 2:1 doi:10.1186/1746-1596-2-1 |
|||
